In addition to APOA-I peptides, the APOA-I Milano mutation, containing enhanced anti-inflammatory, anti-atherosclerotic properties and a more potent ABCA1-dependent cholesterol efflux mediator, has also shown promising therapeutic potential for AD treatment. This evidence concerns the gene APOA1 and Alzheimer disease.